Read Time: 3 mins

55/Invasive assessment of haemodynamic compromise and coronary blood flow during simulated VT

Copy Link
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr55
Authors: AA Miyazawa (Presenting Author) – Imperial College London, London; AD Arnold – Imperial College London, London; H Seligman – Imperial College London, London; N Ali – Imperial College London, London; S Bangi – Imperial College London, London; M Liistro – Imperial College London, London; D Keene – Imperial College London, London; MJ Shun-Shin – Imperial College London, London; R Petraco – Imperial College London, London; ZI Whinnett – Imperial College London, London
Quick Links:
Article Information

Introduction: Reducing unnecessary and inappropriate implantable cardioverter defibrillator (ICD) therapies reduces mortality. This was demonstrated in studies that investigated using higher rates for treatment zones and longer detection windows. ICDs currently do not utilise haemodynamic measurements to guide therapies. We have previously shown that a potentially implantable sensor can reliably identify loss of perfusion in ventricular fibrillation. It is possible that programming even longer detection windows could further reduce unnecessary shocks; however, it is not known in how many patients this may be beneficial, and the risk with adopting this approach is that appropriate shocks would be withheld for longer than necessary in the presence of reduced coronary blood flow (CBF). A disadvantage of using higher heart rate zones is that slower haemodynamically compromising VTs are left untreated. We investigated the impact of simulated VT on CBF and invasive blood pressure (BP). The aims were to determine whether detection windows could potentially be safely extended in some patients during VT and to identify what proportion of patients poorly tolerate episodes of slower VT.

Methods: We recruited patients undergoing a clinically indicated invasive coronary angiogram. We simulated VT by delivering right ventricular VVI pacing, via a temporary wire. Each patient underwent a randomized ventricular pacing (Vp) protocol (140, 160, 180 and 200 bpm) for a minimum of 30 seconds. During each Vp protocol, continuous 3-lead ECG, invasive beat-by-beat arterial BP and invasive CBF, using a combowire in the mid-left anterior descending artery, were recorded. Significant haemodynamic compromise was defined as a reduction in CBF and/or a sustained drop of 30% in systolic BP (SBP) compared with measurements made during baseline rhythm.

Results: A total of 21 patients were recruited, of whom 8 (38%) were female. The mean age was 65 years, and 5 patients (24%) had a left ventricular ejection fraction less than 35%. Data were collected during 145 simulated VT episodes (25 at 200 bpm, 42 at 180 bpm, 39 at 160 and 140 bpm, and 38 at 120 bpm). Results showed that 28% of simulated VT episodes at a rate of 200 bpm were haemodynamically tolerated. This suggests that ICD therapies could potentially be delayed for longer during these VT episodes to allow more time for VT to self-terminate. Haemodynamic compromise was observed in a proportion of slower simulated VT episodes (rates that are below current guidelines for primary prevention programming). For the combined endpoint of decline in CBF and SBP, VT was not tolerated in 11 (28.9%) at 120 bpm, 12 (30.8%) at 140 bpm, 22 (56.4%) at 160 bpm and 28 (66.7%) at 180 bpm. An isolated reduction in CBF had a greater impact on haemodynamic compromise at slower rates (9 (23.7%) at 120 bpm vs 1 (2.6%) at 160 bpm), whereas faster rates were driven by sustained drops in SBP. Proportionally, more patients had haemodynamic compromise at higher heart rates compared with slower heart rates (p=0.016).

Conclusion: One-third of simulated VT episodes at 200 bpm were haemodynamically well tolerated. This suggests VT detection windows could potentially be safely extended, with the aim of reducing unnecessary therapies in a significant number of VT episodes. In contrast, many episodes of slower VT were poorly tolerated, implying that therapies may be beneficial. Thus, ICD programming could be further optimized with haemodynamically guided therapies compared with currently used methods, which exclusively rely on the electrogram.

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72